Status:
COMPLETED
Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborating Sponsors:
Heart and Stroke Foundation of Ontario
University of Ottawa
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
More than 80% of patients with end stage renal disease have hypertension; 70% of whom are poorly controlled using conventional Hemodialysis therapy. An expanded extracellular fluid volume and an incre...
Detailed Description
Patients with end stage renal disease have an adjusted risk of cardiovascular mortality that is 10-20 times greater than the general population. Of the modifiable risk factors, hypertension occurs in ...
Eligibility Criteria
Inclusion
- Systolic Hypertension
- They are able to make the time commitment for daily therapy
- They are capable of giving informed consent.
Exclusion
- They are expected to receive a transplant within the next 12 months
- If they are considering a switch to peritoneal dialysis
- They are not expected to survive 12 months
- They have infections that require isolation (Vancomycin Resistant Enterococcus, Methicillin Resistant Staphylococcus Aureus, Hepatitis B)
- They have known symptomatic dilated cardiomyopathy (New York Association Class II or III with left ventricle ejection fraction of \<0.35
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00759967
Start Date
September 1 2007
End Date
June 1 2012
Last Update
August 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 7W9